PubRank

D M Pardoll

Author PubWeight™ 139.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001 6.97
2 Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996 6.03
3 Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 1989 4.19
4 Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990 3.98
5 A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature 1987 3.96
6 A fixed site of DNA replication in eucaryotic cells. Cell 1980 3.78
7 Molecular and cellular events of T cell development. Adv Immunol 1989 3.50
8 Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001 3.27
9 Supercoiled loops and eucaryotic DNA replicaton. Cell 1980 3.24
10 Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000 2.91
11 Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage. Nature 1988 2.84
12 Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991 2.81
13 CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 1998 2.69
14 Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci U S A 1987 2.57
15 Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 1999 2.55
16 Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes. Science 1986 2.40
17 Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995 2.27
18 The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996 2.24
19 Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000 2.13
20 Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 1998 2.10
21 Effects of cyclosporine A on T cell development and clonal deletion. Science 1988 2.08
22 T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev 1987 2.07
23 In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994 2.01
24 Differential expression of two distinct T-cell receptors during thymocyte development. Nature 1987 1.95
25 Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A 1998 1.95
26 The fate of CD4-8- T cell receptor-alpha beta+ thymocytes. J Immunol 1991 1.90
27 Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995 1.90
28 In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996 1.89
29 Localization of SV40 genes within supercoiled loop domains. Nucleic Acids Res 1980 1.68
30 Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999 1.63
31 Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med 1987 1.63
32 Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997 1.58
33 Tumour antigens. A new look for the 1990s. Nature 1994 1.56
34 CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 2000 1.48
35 A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995 1.44
36 Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000 1.41
37 Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998 1.38
38 In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol 2000 1.36
39 Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A 1999 1.30
40 The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul 1978 1.23
41 Sequence analysis of nuclear matrix associated DNA from rat liver. Exp Cell Res 1980 1.17
42 Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994 1.17
43 Early genetic events in T cell development analyzed by in situ hybridization. J Exp Med 1987 1.16
44 Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996 1.13
45 Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000 1.08
46 Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998 1.08
47 Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. J Immunol 1988 1.04
48 The unfolding story of T cell receptor gamma. FASEB J 1987 1.04
49 Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993 1.03
50 Activation properties of T cell receptor-gamma delta hybridomas expressing diversity in both gamma- and delta-chains. J Immunol 1988 1.03
51 Molecular mechanisms for lineage commitment in T cell development. Semin Immunol 1990 0.98
52 Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996 0.97
53 Cyclosporin A inhibits positive selection and delays negative selection in alpha beta TCR transgenic mice. J Immunol 1994 0.94
54 Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 1998 0.94
55 Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan. Transplantation 1993 0.94
56 Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood 1991 0.93
57 Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 2001 0.91
58 Murine tumor antigens: is it worth the search? Curr Opin Immunol 1996 0.91
59 Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol 2001 0.89
60 Aplastic crisis due to extensive bone marrow necrosis in sickle cell disease. Arch Intern Med 1982 0.89
61 T cell receptor gamma/delta chain diversity. J Exp Med 1988 0.89
62 Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. Blood 1986 0.89
63 Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 1995 0.88
64 Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats. Stroke 1997 0.88
65 Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000 0.85
66 Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol 1996 0.84
67 High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993 0.84
68 An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. J Immunol 2001 0.83
69 Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 1999 0.83
70 Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 2001 0.83
71 Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999 0.81
72 Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 1997 0.81
73 Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J Neurosurg 2000 0.81
74 Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. J Hepatol 2000 0.80
75 A murine thymocyte clone expressing gamma delta T cell receptor mediates natural killer-like cytolytic function and TH1-like lymphokine production. Cell Immunol 1990 0.79
76 Selective association between MHC class I-restricted T cell receptors, CDS, and activated tyrosine kinases on thymocytes undergoing positive selection. J Immunol 1992 0.79
77 Homozygous alpha thalassemia/Hb G Philadelphia. Hemoglobin 1982 0.79
78 Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer. Laryngoscope 1999 0.78
79 Can bone marrow-derived thymic stromal cells mediate the positive selection of class I-restricted T cells? Cell Immunol 1996 0.78
80 Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol 1995 0.78
81 Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother (1991) 1992 0.78
82 Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. J Surg Oncol 1999 0.78
83 Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother 2000 0.77
84 Comparative analysis of paracrine immunotherapy in experimental brain tumors. Neurosurg Focus 2000 0.77
85 Self-reactive T cells are present in the peripheral lymphoid tissues of cyclosporin A-treated mice. Int Immunol 1992 0.77
86 Are the IL-2 receptors expressed in the murine fetal thymus functional? Dev Immunol 1990 0.77
87 Gene therapy: its potential applications in the treatment of renal-cell carcinoma. Semin Oncol 1995 0.75
88 The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy. Immunol Res 1993 0.75
89 Tyrosine kinase triggering in thymocytes undergoing positive selection. Eur J Immunol 1992 0.75